According to the latest financial report of Noile-Immune Biotech, the latest earnings per share (TTM) for the company is -7.93. Investing in companies with strong earnings per share can potentially provide higher returns.
Interested in knowing about Noile-Immune Biotech's free cash flow? The latest report shows it as --. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Noile-Immune Biotech shows that the company's current ratio is 66.55, indicating healthy liquidity.
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Noile-Immune Biotech, the quick ratio is 65.05, indicating that the company can meet its short-term debt obligations.
Want to learn more about the financial health of Noile-Immune Biotech? The latest ROE figure is -6.63%, indicating that the company has stable profitability.
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Noile-Immune Biotech, the total asset return on investment (ROA) is -6.51%.
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Noile-Immune Biotech's latest financial report to see how their gross margin is doing - currently at 92.46%.
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Noile-Immune Biotech, the net profit margin is -13.15K%, which is a good sign for its profitability.